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To study the role of the neurofibromatosis-1 (NF1) gene in mammalian brain development, we recently
generated mice in which Nf1 gene inactivation occurs in neuroglial progenitor cells using the brain lipid bind-
ing protein (BLBP) promoter. We found that Nf1BLBPCKO mice exhibit significantly reduced body weights and
anterior pituitary gland sizes. We further demonstrate that the small anterior pituitary size reflects loss of neu-
rofibromin expression in the hypothalamus, leading to reduced growth hormone releasing hormone, pituitary
growth hormone (GH) and liver insulin-like growth factor-1 (IGF1) production. Since neurofibromin both
negatively regulates Ras activity and positively modulates cAMP levels, we examined the signaling pathway
responsible for these abnormalities. While BLBP-mediated expression of an activated Ras molecule did not
recapitulate the body weight and hypothalamic/pituitary defects, treatment of Nf1BLBPCKO mice with rolipram
to increase cAMP levels resulted in a partial restoration of the body weight phenotype. Furthermore, con-
ditional expression of the Ras regulatory GAP domain of neurofibromin also did not rescue the body
weight or Igf1 mRNA defects in Nf1BLBPCKO mice. Collectively, these data demonstrate a critical role for neu-
rofibromin in hypothalamic–pituitary axis function and provide further insights into the short stature and GH
deficits seen in children with NF1.
INTRODUCTION
Short stature is a common problem in children and young
adults with the inherited tumor predisposition, neurofibroma-
tosis type 1 (NF1). Thirteen to eighteen percent of individuals
with NF1 exhibit stature measurements greater than two stan-
dard deviations below the population norm (1,2). While mul-
tiple etiologies could underlie this growth defect, abnormal
hypothalamic–pituitary axis function has been hypothesized
to play a causative role (3). In the largest study of pituitary
function in children with NF1 and short stature, nearly 80%
of these children (15/19 patients) were found to have growth
hormone (GH) deficiency in the absence of suprasellar
abnormalities on neuroimaging (4).
The NF1 gene encodes a large cytoplasmic protein, termed
neurofibromin, which was originally demonstrated to function
as a negative regulator of Ras (5). Within the neurofibromin
predicted coding sequence are 300 amino acids which com-
prise the GTPase-activating protein (GAP) domain (6–8).
Consistent with the proposed role of neurofibromin as a Ras
GAP, loss of Nf1 expression in numerous mammalian cell
types results in increased Ras activity and downstream
MAPK/Akt signaling (9,10). In addition, replacement of this
GAP-related domain in astrocytes, fibroblasts and Schwann
cells restores normal Ras activity and reverses the growth
advantage that results from Nf1 inactivation (11–13).
While neurofibromin is thought to primarily regulate cell
growth by modulating Ras activity, studies in both Drosophila
and mouse tissues have shown that neurofibromin also posi-
tively regulates intracellular cAMP levels (14–16). Analysis
of Nf12/2 embryonic forebrain homogenates and primary
neuronal cultures demonstrated lower cAMP levels compared
with wild-type (WT) controls (16). In astrocytes, neurofibro-
min regulation of cAMP contributes to the increased cell sur-
vival and growth observed in cultured Nf12/2 astrocytes
(14,17). During differentiation from neural progenitor cells,
neurofibromin regulates neuronal maturation in vitro and
in vivo in a cAMP-dependent manner (18). In contrast, the
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increased gliogenesis that results from neurofibromin
deficiency in neuroglial progenitor cells requires Ras and
Akt activation in vivo (18). These studies suggest that neuro-
fibromin may function in the mammalian central nervous
system (CNS) by modulating either Ras- or cAMP-dependent
pathways.
Relevant to the short stature observed in individuals with
NF1, previous studies in Drosophila have shown that Nf1
mutant flies have reduced body size at the larval, pupal
and adult stages, which was not restored by manipulating
Ras1 signaling (19). Instead, the size defect was partially
corrected by the expression of an activated adenosine 30,
50-monophosphate-dependent protein kinase (PKA) molecule.
Subsequent studies from this group revealed that this mutant
Drosophila phenotype reflects de-regulated Ras2 function
in neurofibromin-deficient fly tissues (20). However, in
Nf12/2 mouse cells, R-Ras2 activation leads to increased
signaling through the phosphatidylinositol 3-kinase (PI3-
kinase) and MAP kinase pathways (21). To explore the
role of the NF1 gene in body size regulation in mice, we
used a recently developed mouse strain in which Nf1 inacti-
vation occurs in neural stem/progenitor cells (Nf1BLBPCKO
mice). In this report, we demonstrate that neurofibromin
regulates hypothalamic–pituitary axis function in a Ras-
independent fashion.
RESULTS
Nf1BLBPCKO mice exhibit reduced anterior pituitary
gland size
We inactivated the Nf1 gene in embryonic neural stem/
progenitor cells within the developing CNS by Cre-mediated
recombination using a 1.6 kb fragment of the mouse Blbp
promoter as previously reported (18). Cre recombinase activity
was detected throughout the mouse CNS using either
BLBP-Cre;Rosa-YFP or BLBP-Cre;LSL-myr-Akt reporter
mouse crosses (18,22). Nf1BLBPCKO mice were born at the
expected Mendelian ratios and initially appeared normal.
However, during the first week of life, Nf1BLBPCKO mice dis-
played severe growth retardation, resulting in .60% lower
body weights compared with BLBP-Cre; Nf1flox/wt (HET) or
WT littermates by 3 weeks of age (Fig. 1A and B). No normal-
ization of body weight was observed later during postnatal
development: The few mice that survived to 2 or 3 months of
age retained this growth deficit, reaching about 30% of the
weight of WT littermates (data not shown). Both male and
female mice exhibited similar growth retardation. Complete
necropsies of Nf1BLBPCKO mice failed to reveal any gross or
microscopic abnormalities to account for the observed growth
failure, and abundant milk was detected in the stomachs of
Nf1BLBPCKO pups (data not shown). Upon careful examination
of the skull base after removal of the brain, the pituitary gland
was found to be smaller in Nf1BLBPCKO mice (Fig. 1C). Fol-
lowing dissection of the pituitary gland, the posterior lobes
were of normal size in mice of all genotypes (Fig. 1D);
however, the anterior pituitary was significantly smaller in
Nf1BLBPCKO mice compared with heterozygous or WT
littermates (Fig. 1E).
Impaired hypothalamic releasing hormone production
in Nf1BLBPCKO mice
Early Nf1 gene inactivation in embryonic neural stem/progeni-
tor cells leads to widespread loss of neurofibromin expression
throughout the CNS, including the hypothalamus. Immunohis-
tochemical staining demonstrated a 75% reduction in the
number of neurofibromin-expressing cells (Fig. 2A) and a
60% reduction in Nf1 mRNA by quantitative real-time PCR
(qPCR) in the postnatal hypothalamus (Fig. 2B). In contrast,
there was no significant change in Nf1 mRNA expression in
the pituitary gland.
Since growth hormone releasing hormone (GHRH) is a criti-
cal factor in the development of the hypothalamic–pituitary axis
(23), we analyzedGHRHexpression by immunohistochemistry.
We found a significant reduction in GHRH staining within the
median eminence, the primary capillary network of the hypo-
physeal portal system (Fig. 2C). Next, we sought to determine
whether the production of releasing hormones in neuroendo-
crine cells of the hypothalamus was altered in Nf1BLBPCKO
mice. Using qPCR, we found a 40–60% reduction in the
levels of Ghrh, Gnrh and Trh mRNA in Nf1BLBPCKO mice
compared with WT controls (Fig. 2D). Interestingly, the
pattern of growth retardation described in transgenic rat and
mice models with reduced GHRH production or impaired
GHRH receptor function was similar to the phenotype we
observed in Nf1BLBPCKO mice (24–26). These observations
coupledwith our results suggest that neurofibromin is an import-
ant regulator of the hypothalamic–pituitary axis and Ghrh
expression.
Nf1BLBPCKO mice have altered hormone production
in the pituitary gland
As GHRH is a major regulator of postnatal pituitary develop-
ment, we quantified the number of proliferating cells in the
pituitary gland (Fig. 3A). There was a 3-fold reduction in
the number of BrdU-incorporating cells throughout the
anterior lobe of pituitary glands from Nf1BLBPCKO mice com-
pared with WT or HET littermate controls at postnatal day
(PN) 18 (Fig. 3B). No changes in BrdU incorporation were
seen in the neurohypophysis (data not shown). In addition,
we found that the number of apoptotic cells was unchanged
in either part of the gland, as determined by TUNEL labeling
(data not shown). To determine whether neurofibromin loss in
the hypothalamus resulted in impaired pituitary hormone pro-
duction, we next counted the number of ACTH-expressing
cells in the anterior lobe by immunohistochemistry
(Fig. 3C). The number of ACTH-labeled cells in the gland
was not decreased in Nf1BLBPCKO mice compared with litter-
mate controls (Fig. 3D). Moreover, there was no change in the
levels of Tsh1b mRNA in Nf1BLBPCKO mouse pituitary
glands at PN18 by qPCR (Fig. 3E).
In contrast, GHandprolactin (PRL)mRNAlevelswere signifi-
cantly reduced in the pituitary glands of Nf1BLBPCKO mice
(Fig. 3E). To determine the functional consequence of reduced
GH production in Nf1BLBPCKO mice, we measured Igf1
mRNA levels in the liver at PN18 as a surrogate marker of circu-
lating GH.We found a 65% reduction in liver Igf1mRNA levels
in Nf1BLBPCKO mice compared with littermate controls
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(Fig. 3F).Thedifferential effect of neurofibromin losson pituitary
hormone production suggests that somatotropes and mammo-
tropes are more severely affected by hypothalamic Nf1 loss (27).
The early development of the hypothalamic–pituitary axis
is orchestrated by a number of transcription factors. We
selected a panel of these hypothalamic–pituitary axis tran-
scriptional regulators (Ikaros1, Mash1, Math3 and Sox3)
based on studies demonstrating that inactivation of these
transcriptional regulation in mice leads to hypopituitary
phenotypes similar to that observed in Nf1BLBPCKO mice
(28–31). Using qPCR, we found no differences in mRNA
expression of these transcriptional factors in the postnatal
Nf1BLBPCKO hypothalamus compared with WT littermates
(Supplementary Material, Fig. S3). These results suggest that
neurofibromin loss does not cause pan-pituitary dysfunction,
but rather leads to selective decreases in anterior pituitary
GH and PRL production, and that these abnormalities do
not reflect alterations in the expression of transcriptional
factors important for normal hypothalamic–pituitary axis
development.
The hypothalamic–pituitary abnormalities in
Nf1BLBPCKO mice are not recapitulated by Ras activation
Previous studies have shown that neurofibromin functions in
part as a major negative regulator of Ras activity. To determine
whether the increased Ras activation seen in the brains of
Nf1BLBPCKO mice accounted for the observed hypothalamic
and pituitary abnormalities, we crossed BLBP-Cre mice with
LSL-KRasG12Dmice (32) to generatemicewithKRas activation
in neural stem/progenitor cells.We chose to express KRas based
on our observation that KRas is hyperactivated in Nf1-deficient
neural stem cells and Nf1BLBPCKO mouse brains (data not
shown). In addition, activated KRas expression in GFAPþ
cells of Nf1þ/2 mice resulted in optic gliomas, similar to
Nf1þ/2 mice lacking neurofibromin expression in GFAPþ
cells, while KRas hyperactivation in neural stem/progenitor
cells (NSCs) produced an identical gliogenesis abnormality as
neurofibromin loss in NSCs (11,18). In contrast to Nf1BLBPCKO
mice, BLBP-Cre; LSL-KRasG12D (KRas) mice did not display
significant growth retardation (Fig. 4A). We found no significant
Figure 1. Decreased anterior pituitary size in Nf1BLBPCKO (CKO) mice. (A) Postnatal growth was impaired in CKO mice resulting in proportionately smaller
mice. (B) Body weights were significantly reduced in CKO, but not in BLBP-Cre; Nf1flox/wt (HET) or wild-type (WT), mice. (C) The entire pituitary gland
appeared smaller in CKO mice in situ. Photomicrographs demonstrate the pituitary gland at the base of the skull. (D) Dissection of the pituitary gland revealed
a disproportionate reduction in anterior pituitary size (lower image) with normal posterior pituitary size (upper image). (E) The surface area covered by the
anterior lobe was significantly reduced in CKO mice. Asterisks denote statistically significant differences from control littermates (P , 0.05).
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decrease in pituitary gland size (Fig. 4B), pituitary cell prolifer-
ation (Fig. 4C) or Ghrh mRNA levels (Fig. 4D). Similarly,
there was no growth retardation or impaired pituitary develop-
ment in BLBP-Cre; LSL-myr-Akt mice that express a
constitutively active form of Akt, an important downstream
effector of Ras (data not shown). Collectively, these results indi-
cate that the hypothalamic and pituitary abnormalities associ-
ated with neurofibromin loss in the brain are not Ras-dependent.
Expression of the neurofibromin GAP-related domain
does not rescue the growth abnormalities
seen in Nf1BLBPCKO mice
Loss of neurofibromin results in Ras hyperactivation as well as
increased activity of Ras downstream effectors, including Akt
and Erk. Consistent with the role of neurofibromin as a
Ras GTPase-activating protein, we observed a gene dose-
dependent increase in the number of activated
phospho-Erk1/2-labeled cells in hypothalamic tissue from
Nf1BLBPCKO mice at 2 weeks of age (Fig. 5A and B).
However, despite the marked hyperactivation of these MAP
kinases in the HET mice, there was no evidence of any
growth retardation or hypothalamic abnormalities in these
mice. These results are consistent with the above findings
that KRas activation in neural stem/progenitor cells in vivo
did not result in hypothalamic–pituitary or somatic growth
defects. In light of previous studies in Nf12/2 cells
showing that R-Ras activation leads to increased MAPK and
Akt activation coupled with the results described above
using KRas and Akt mice, it is unlikely that de-regulated
Ras (or R-Ras) signaling accounts for the hypothalamic–
pituitary axis and somatic growth abnormalities observed in
Nf1BLBPCKO mice.
Since mice with KRas or Akt activation do not exhibit
abnormalities in hypothalamic–pituitary function, we next
sought to determine whether expressing the Ras regulatory
domain of neurofibromin in vivo would rescue the growth
retardation observed in Nf1BLBPCKO (CKO) mice. For these
experiments, we bred Nf1flox/flox mice with Rosa-HA-GRD
mice (33), which express the human GAP-related domain
(GRD) from the Rosa promoter following Cre-mediated
recombination. BLBP-Cre; Nf1flox/wt mice were then crossed
with Rosa-HA-GRD; Nf1flox/flox mice to generate BLBP-Cre;
Rosa-HA-GRD; Nf1flox/flox mice (CKOþGRD mice). As
demonstrated by Epstein and coworkers (33), we similarly
found that CKO þ GRD mice had levels of Erk1/2 activation
(surrogate marker of Ras activity) similar to WT mice
(Fig. 6A), demonstrating that the Ras regulatory function of
neurofibromin was restored by GRD expression. However,
CKO þ GRD mice exhibited the same smaller anterior pitu-
itary sizes (data not shown), reduced body weights (Fig. 6B)
and liver Igf1 mRNA levels (Fig. 6C) as seen in their CKO lit-
termates. Taken together, these results demonstrate that the
growth abnormalities observed in Nf1BLBPCKO mice are not
dependent on neurofibromin Ras GAP function.
Molecular mechanism of neurofibromin-induced
hypopituitarism
In addition to negatively regulating Ras activity, neurofibro-
min has been shown to positively regulate cAMP generation
in the brain (16). Since Ras activation did not recapitulate
Figure 2. Hypothalamic loss of neurofibromin alters releasing hormone generation. (A) The number of neurofibromin-expressing cells was greatly reduced in the
CKO hypothalamus. The inset shows individual labeled cells. (B) Nf1 mRNA levels (normalized to b-actin) were lower in the hypothalamus, but not in the
pituitary gland, of CKO mice as measured by quantitative real-time PCR. (C) GHRH immunolabeling was reduced in the median eminence of CKO mice.
(D) Ghrh, Gnrh and Trh mRNA levels were reduced in the Nf1BLBPCKO hypothalamus compared with littermate controls. Asterisks denote statistically signifi-
cant differences from control littermates (P , 0.05). Scale bars, 100 mm, for the inset 10 mm.
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the hypothalamic or pituitary abnormalities observed in
Nf1BLBPCKO mice, we next sought to determine whether
loss of neurofibromin alters cAMP levels in the hypothalamus.
We observed a 50% decrease in the levels of cAMP in
Nf1BLBPCKO hypothalamic homogenates compared with lit-
termate controls (Fig. 7A). These reduced cAMP levels were
associated with decreased activation of the cAMP responsive
transcription factor, CREB. In this regard, we have previously
shown that PN1 Nf1BLBPCKO mice exhibit decreased hypo-
thalamic CREB activation (18). Consistent with these findings,
loss of CREB expression in the developing CNS leads to
decreased GHRH release from hypothalamic neurons and sub-
sequently causes hypopituitarism (34).
In order to increase cAMP levels inNf1BLBPCKOmice in vivo,
we administered rolipram, a specific phosphodiesterase-4
inhibitor (35). Rolipram has been shown to elevate CREB
activation in the brain following intraperitoneal delivery
(36). For these experiments, rolipram was injected daily
from E11.5 to PN18 to timed-pregnant dams and to their
pups from PN7 through PN18. We have previously shown
that rolipram injection partially restored cAMP levels in the
forebrains of Nf1BLBPCKO mice and corrected the cortical
thickness defect associated with Nf1 loss (18). Following
rolipram treatment of Nf1BLBPCKO mice, there was a signifi-
cant increase in body weight compared with untreated age-
matched Nf1BLBPCKO mice at 2 weeks of age; however, the
rolipram-injected mice were still smaller than littermate
controls (Fig. 7B). In contrast, rolipram had no effect on
the weights of WT or HET mice. The fact that inhibition of
phosphodiesterase activity partially rescues the phenotype
is consistent with previous studies demonstrating that
neurofibromin increases the production of cAMP by activating
adenylyl cyclase (14,16), and that forskolin, an adenylyl
cyclase activator, stimulates the release of GHRH in a
Figure 3. Impaired pituitary growth and hormone production. (A) Immunofluorescence detection of BrdU incorporation in the pituitary gland. (B) There was a
significant reduction in the number of BrdUþ (proliferating) cells in the anterior pituitary. (C) ACTH immunohistochemistry showed normal labeling in CKO
mice. (D) Nf1 loss did not affect the number of ACTHþ cells. (E) GH and PRL mRNA levels were significantly reduced in the CKO mice, while Tsh1b mRNA
levels were unchanged compared with WT controls. (F) Igf1 mRNA levels were significantly lower in the livers of CKO mice. Asterisks denote statistically
significant differences from control littermates (P , 0.05). Scale bars, 100 mm.
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concentration-dependent fashion (37). Moreover, the magni-
tude of the body weight rescue following rolipram treatment
(50%) is similar to that observed following PKA expression
in Nf12/2 Drosophila (19).
DISCUSSION
One common feature of individuals with NF1 is relatively
short stature compared with their unaffected siblings. The
Figure 4. Constitutive activation KRas does not impair somatic growth. (A) The modest decrease in body weights of BLBP-Cre; LSL-KRas (KRas) mice was
not statistically significant. (B) No significant change in the surface area of the anterior pituitary was seen in KRas mice. (C) The number of Ki67-labeled nuclei
was unchanged in KRas mice. (D) The slight reduction in Ghrh levels in the hypothalamus was not statistically significant, as determined by qPCR. Asterisks
denote statistically significant differences from control littermates (P , 0.05).
Figure 5. Erk activation does not correlate with the somatic growth defects in Nf1BLBPCKO mice. (A) Increased activation of Erk1/2 was observed in the hypo-
thalamus from both HET and CKO mice compared with WT controls. The inset shows individual labeled cells. (B) There was a significant gene dose-dependent
increase in the number of phospho-Erk1/2 labeled cells in the hypothalamus. Scale bars, 100 mm, for the inset 30 mm.
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observation that some of these children have either subclinical
or overt GH deficiency prompted us to examine somatic
growth in a recently developed Nf1 mutant mouse. In the
present study, we demonstrate that neurofibromin regulates
the function of the hypothalamic–pituitary axis and that Nf1
loss in the brain leads to decreased GH and IGF levels.
Previous studies of Nf1-deficient Drosophila have similarly
shown that neurofibromin regulates growth at the organismal
level (19), and have implicated a select neuronal population
in the developing larval CNS (20,38). Consistent with the
idea that the growth defect may reflect the impact of neurofi-
bromin loss on neurons, growth deficits have also been
observed in mice with neuron-specific conditional Nf1 inacti-
vation (39). Using the synapsin-1 promoter to induce loss of
neurofibromin expression in neurons by E12.5, growth retar-
dation becomes evident in these Nf1Syn1CKO mice by
PN3-4, analogous to what we observed in Nf1BLBPCKO
mice. In addition, dwarfism has similarly been reported in
mice in which neurofibromin loss occurs in neuroglial pro-
genitors by E11.5 (40). These mice exhibit both neuronal
and astroglial cell loss of neurofibromin, and demonstrate a
significant reduction in body weight by PN8. In contrast,
mice with predominantly glial Nf1 inactivation (41) had
normal body weights and sizes (Supplementary Material,
Fig. S2A). Furthermore, in these mice, we observed no signifi-
cant changes in hypothalamic GHRH expression or liver Igf1
expression (Supplementary Material, Fig. S2B). Together,
these findings suggest that the growth retardation observed
in Nf1 mutant mice and flies is the result of a primary neuronal
defect.
Neurofibromin regulates the development of the nervous
system in both a Ras- and cAMP-dependent fashion. Loss of
neurofibromin results in the expansion of glial cell populations
as a consequence of de-regulated Ras signaling in Nf1 mutant
mice (11). We have recently shown that activation of either
Ras or Akt in neural progenitor cells is sufficient to recapitu-
late the glial abnormalities observed in Nf1BLBPCKO mice,
whereas increasing cAMP levels by inhibiting phosphodiester-
ase activity in the developing brain fails to ameliorate this glial
abnormality (18). In contrast, neurofibromin regulates neur-
onal maturation through Ras-independent mechanisms. In
this regard, Nf1 inactivation in neural progenitors or neurons
results in decreased cortical thickness in vivo (18,39), which
we have recently shown reflects reduced neurite lengths
in vitro and in vivo. Importantly, the cortical thickness and
neurite length phenotypes were not recapitulated by constitu-
tive activation of KRas or Akt, but were restored by increasing
cAMP levels in vitro and in vivo (18). Collectively, these find-
ings suggest that neurofibromin regulates neuronal differen-
tiation by modulating cAMP levels.
Cyclic AMP and the transcription factor cAMP response
element binding protein (CREB) are critical regulators of
hypothalamic–pituitary axis development. A number of key
transcription factors and hormones expressed in the pituitary
gland have CREB binding sites in their promoter regions
(42,43). The physiological importance of cAMP signaling
and CREB activation in the regulation of pituitary GH
production has been elegantly demonstrated using several
genetically engineered mouse strains: Mice with Gh promoter-
driven expression of a non-phosphorylatable CREB have
decreased CREB activity, resulting in dwarfism (44). The
reduced body size in these CREBM1 transgenic mice reflects
atrophy of the anterior pituitary without any effects on the
intermediate or posterior pituitary. In contrast, Gh promoter-
mediated expression of cholera toxin caused increased
cAMP levels and led to pituitary hyperplasia and gigantism
in mice (45). These transgenic mice had significantly larger
body weights and high levels of circulating GH.
The importance of CREB signaling in hypothalamic–
pituitary axis function and short stature is further underscored
Figure 6. Expression of the neurofibromin GAP-related domain (GRD) does not rescue the reduced growth or Igf-1 mRNA levels seen in CKO mice.
(A) NF1-GRD expression in Nf1BLBPCKO mice (CKO GRD) restored Erk1/2 activation (phospho-Erk1/2; p-Erk1/2) to WT levels. (B) In contrast, GRD
expression had no effect on body weight (CKOþGRD mice) compared with CKO littermates. (C) Liver Igf1 mRNA levels were also not changed by GRD
expression. Asterisks denote statistically significant differences from control littermates (P , 0.05).
Figure 7. Cyclic AMP levels, but not Erk activation, correlates with the
somatic growth defects in Nf1BLBPCKO mice. (A) Cyclic AMP levels, as
measured by enzyme immunoassay, were significantly lower in the hypothala-
mus of CKO mice. (B) Daily rolipram treatment partially restored the somatic
growth defect. At 2 weeks of age, both the untreated and the rolipram-injected
CKO mice were significantly smaller than their WT littermates (P, 0.005;
asterisks); however, rolipram treatment significantly increased the body
weights of Nf1BLBPCKO mice (P ¼ 0.01; ‘†’).
2962 Human Molecular Genetics, 2008, Vol. 17, No. 19
by the identification of mutations in the CREB binding protein
CBP in Rubinstein–Taybi syndrome. Similar to children with
NF1, children with Rubinstein–Taybi syndrome have poor
growth during the first few months of life, resulting in short
stature (46). In addition, mice expressing a truncated CBP
gene exhibit growth retardation (47). Of note, GH deficiency
has also been reported in some cases of Rubinstein–Taybi
syndrome (48).
In addition, cAMP and CREB are major regulators of
hypothalamic development. In vitro, cAMP modulates the
functional development of hypothalamic neurons (49). In
these studies, forskolin treatment produced similar effects as
cholera toxin, suggesting that cAMP was critical for hypo-
thalamic neuronal maturation. Similarly, rolipram treatment
significantly increased the length of dendrites in hippocampal
neurons in vivo (36). Forskolin and cAMP analogs also
increase neurite extension and functional maturation in
hypothalamic neurons in vitro (50). These observations are
consistent with our findings that forskolin treatment reversed
the Nf1-deficient neuronal neurite length defect in vitro and
that increasing brain cAMP levels by rolipram treatment
resulted in a partial rescue of the growth retardation phenotype
in vivo (18).
The importance of CREB in hypothalamic function is
underscored by the following observations: First, CREB med-
iates developmental gap junction uncoupling during the post-
natal development of hypothalamic neurons in vitro (51).
These gap junctions act as electrical synapses and allow
cAMP and other signaling molecules to coordinate transcrip-
tional activities in developing hypothalamic neurons.
Second, brain-specific loss of CREB results in hypopituitarism
and dwarfism (34). While CREB is normally expressed in
the pituitary glands of these mice, the lack of CREB activity
in the hypothalamus resulted in a robust decrease in GHRH
release into the portal system of the median eminence.
Similar to Nf1BLBPCKO mice, Creb-deficient mice had body
weight reductions which reached statistical significance
at PN8.
Genetically engineered Nf1 mouse models have already
begun to provide fundamentally important insights into the
pathogenesis of numerous NF1-associated phenotypes, includ-
ing plexiform neurofibroma (52), optic glioma (53), leukemia
(54) and malignant peripheral nerve sheath tumors (55,56) as
well as non-neoplastic features, such as bone and vascular
abnormalities (57,58). The Nf1BLBPCKO mouse model
described herein was used to identify an understudied abnorm-
ality in children with NF1. Given the lack of autopsy studies
on NF1 patient brains, limited information is available about
the structure or composition of the hypothalamus and pituitary
gland in individuals with NF1. However, using Nf1BLBPCKO
mice, we found that somatic growth resulting from hypothala-
mic–pituitary dysfunction reflects abnormal Ras-independent
signaling resulting from Nf1 inactivation in neural progenitors.
These findings have relevance to the human condition in that
they uncover a responsible signaling pathway and suggest that
future studies might measure circulating IGF1 or GH levels in
children with NF1 to identify subclinical hypothalamic–pitu-
itary dysfunction.
Interestingly, despite the reduced body weights and organ
sizes, the brain weights of Nf1BLBPCKO mice are unchanged.
These disproportional changes result in relative megalence-
phaly, similar to what has been reported for children with
NF1 (1,59). The relative megalencephaly could reflect
increased numbers of glial precursors, oligodendrocytes or
astrocytes (18). In support of this hypothesis, magnetic reson-
ance imaging studies have found increases in both grey and
white matter volumes in the brains of children with NF1
(60–62).
Collectively, these data demonstrate for the first time that
neurofibromin regulates hypothalamic function and pituitary
development in the mammalian CNS by modulating intra-
cellular cAMP levels. The observation that Nf1 inactivation
in neural progenitor cells results in decreased GH and IGF1
levels is exciting in light of the short stature seen in individ-
uals affected with NF1. Finally, the finding that neurofibromin
regulates hypothalamic and pituitary function in part by con-
trolling cAMP levels offers unique insights into the mechan-
isms underlying NF1-associated growth abnormalities and
may lead to future therapies that target this neurofibromin-
regulated pathway.
MATERIALS AND METHODS
Mice and tissue preparation
BLBP-Cre transgenic mice were successively intercrossed
with Nf1flox/flox mice (39) to generate BLBP-Cre; Nf1flox/flox
(Nf1BLBPCKO or ‘CKO’) mice. BLBP-Cre mice were also
crossed with Lox-stop-lox (LSL)-KRasG12D or Lox-stop-lox
(LSL)-myr-Akt mice to generate BLBP-Cre; LSL-KRasG12D
(KRas) or BLBP-Cre; LSL-myr-Akt mice (Akt), respect-
ively. Rosa-GRD (33) mice were bred with Nf1flox/flox and sub-
sequently with BLBP-Cre; Nf1flox/wt mice in order to generate
BLBP-Cre; Rosa-GRD;Nf1flox/flox (CKOþGRD). All strains
were maintained on a C57BL/6 background and used in
accordance with established and approved mouse protocols
at Washington University.
PN18 mice were intraperitoneally injected with BrdU 3 h
prior to euthanasia. Mice were perfused transcardially with
PBS. A small portion of the liver was removed and snap-
frozen before perfusion with 4% PFA in PBS. Following over-
night post-fixation at 48C, the pituitary glands and 2 mm brain
slices were transferred to 70% ethanol solution prior to paraf-
fin embedding and sectioning. For RNA preparation, mice
were terminally anaesthetized and the brains and pituitary
glands were quickly removed, dissected and snap frozen.
Pituitary size measurement
The dissected pituitary glands were photographed under a dis-
secting microscope and the entire pituitary gland as well as the
posterior pituitary was manually circumscribed and the area
determined using SysImage (Soft Imaging System, Lakewood,
CO) image analysis software (Supplementary Material,
Fig. S1). The anterior pituitary area was estimated by subtract-
ing the posterior pituitary area from the size of the entire pitu-
itary gland. For each genotype, four dissected pituitary glands
were measured from 18-day-old mice of both sexes. WT and
heterozygous littermates were included for comparison.
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Immunohistochemistry
Five-micron paraffin sections were deparaffinized, treated for
citrate antigen retrieval and incubated in 5% serum blocking
solution prior to the overnight incubation of primary anti-
bodies at 48C for 18 h. ACTH, GHRH and Ki67 antibodies
were purchased from Peninsula Lab (San Carlos, CA),
Abcam (Cambridge, MA) and BD Pharmingen (San Jose,
CA), respectively. Antibodies against phospho-CREB and
phospho-Erk1/2 were obtained from Cell Signaling Technol-
ogy, Danvers, MA. Horseradish peroxidase-conjugated sec-
ondary antibodies (Vector Laboratories, Burlingame, CA)
were incubated for 1 h at room temperature (RT) and Vectas-
tain Elite ABC development was employed as previously pub-
lished. Sections were then counterstained with hematoxylin.
For BrdU labeling, deparaffinized sections were treated with
0.1% trypsin in PBS for 10 min at RT. DNA was denatured
by 0.1 M HCl for 10 min at 48C and 4 M HCl for 30 min at
378C followed by two rinses of 0.1 M boric acid (pH ¼ 8.0)
for 5 min at RT prior to blocking. The primary anti- BrdU
antibody (Abcam) was applied overnight at 48C and fluor-
escent detection was performed with Alexa 488-labeled sec-
ondary antibody (Molecular Probes, Eugene, OR) for 60 min
at RT. TUNEL labeling on the paraffin sections was per-
formed according to the manufacturer’s instructions (Roche
Diagnostics, Nutley, NJ). The number of BrdU- and ACTH-
immunoreactive cells as well as of TUNEL-positive cells in
the sections were quantified by direct counting on two non-
consecutive sections for at least three mice in each genotype.
Real-time reverse transcription PCR
Snap frozen tissues (liver, pituitary gland, hypothalamus and
brain) were homogenized in TRIzol reagent (Invitrogen, Carls-
bad, CA) to extract total RNA. Two micrograms of total RNA
extracted from each sample were used to make cDNA. Thirty
nanograms of cDNA were used as a template for the determi-
nation of the transcription of specific genes by real-time PCR
(RT-PCR) using SYBRw Green detection and transcript
specific primers. The primers used were: Nf1 sense (50 AAT
CAG TGG TTA GCC AGC GC 30), Nf1 antisense (50 TTC
ATA CGG CGA GAC AAT GG 30); Gh sense (50 TTC
CAT TCA GAA TGC CCA GG 30), Gh antisense (50 CGA
AGC AAT TCC ATG TCG GT 30); Igf1 sense (50 GCT
GCA AAG GAG AAG GAA AGG 30), Igf1 antisense
(50 TGG CAT TTT CTG CTC CGT G 30); Tsh1b sense
(50 GCA GCA TCC TTT TGT ATT CCC 30), Tsh1b antisense
(50 CCG TGT CAT ACA ATA CCC AGC 30); GHRH
sense (50 GCT GTA TGC CCG GAA AGT GAT 30), Ghrh
antisense (50 AAT CCC TGC AAG ATG CTC TCC 30); Trh
sense (50 GAG GAA GAC GTT GAA GCC GAA 30), TRH
antisense (50 ATC CTT GTC TTG GTT GGC ACG 30);
Gnrh sense (50 TGT GTG TTT GGA AGG CTG CTC 30)
and Gnrh antisense (50 CCT TGC CCA TCT CTT GGA
AAG 30); Ikaros1 sense (50 AGC ACA GCA GAA CTC
CAA GAG TGA 30) and Ikaros1 antisense (50 TTC ATT
TCA CAG GCA CGC CCA TTC 30); Mash1 sense (50 ACG
ACT TGA ACT CTA TGG CGG GTT 30) and Mash1 anti-
sense (50 AAG TCC AGC AGC TCT TGT TCC TCT 30);
Math3 sense (50 AGG AAC TAC ATC TGG GCC TTG
TCT 30) and Math3 antisense (50 TGC TTG TGG GTT
GAG AGA GAC CTT 30); Sox3 sense (50 ACT GGA AAC
TGC TGA CCG ATG 30) and Sox3 antisense (50 TGT CCT
TCT TGA GCA GCG TCT 30). PCR reactions without
cDNA samples were used as negative controls. Each reaction
was performed in duplicate. The fluorescent data were
converted into cycle threshold (CT) measurements, and the
DDCT method was used to calculate fold expression relative
to littermate control samples, using b-actin as an internal
control.
Cyclic AMP measurements
Dissected hypothalamic regions of brains were snap-frozen in
liquid nitrogen, triturated in ice-cold 5% trichloroacetic acid
(10 ml per mg tissue) and centrifuged at 1000g for 10 min at
48C. Supernatants supplemented with equal volume of 0.1 M
HCl were extracted with water-saturated ether thrice prior to
desiccation in a vacuum centrifuge. The cAMP content was
determined using a cyclic AMP enzyme immunoassay kit
(Assay Designs, Ann Arbor, MI).
Statistical analysis
Each experiment was performed with samples from at least
three mice for each genotype or treatment condition. Statistical
significance (P , 0.05) was determined by paired or unpaired
t-test (with Welch’s Correction) using GraphPad Prism 4.0
software (GraphPad Inc., San Diego, CA).
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